Transperineal Biopsy IDs Active Surveillance Candidates

Published Date: 29 Jul 2026

Transperineal 3D mapping biopsy may help select patients with low-risk prostate cancer who are most likely to fare well with active surveillance.

Read Full News

Latest News

Palliative Care Remains Uncommon in Young Adults With Cancer

Concurrent palliative care use among young adults with advanced cancer is less than 20%, with substantial variation across cancer types.

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

In high-risk low-grade glioma, starting with temozolomide or radiotherapy yields similar survival.

Stem Cell Transplant Associated With Better PFS in NKTCL

Researchers aim to evaluate the effectiveness of ASCT as consolidation therapy for patients with advanced-stage natural killer/T-cell lymphoma who have attained their first complete remission.

In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events

A lung cancer trial was stopped early due to a high rate of fatal adverse events with the addition of thoracic radiotherapy to standard maintenance immunotherapy.

Smoldering Myeloma: The Treatment Issue Is Getting Trickier

An FDA approval, striking CAR T data, and a field that can't agree on what to do next. Experts weigh in on the most contentious question in myeloma.

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

Todays Updates

Schizophrenia: Nighttime Light Tied to Metabolic Dysfunction

Higher vs lower nighttime light exposure is associated with increased risk for obesity, hypertension, and dyslipidemia in patients with schizophrenia, a study suggests.

The Clues Hidden in Failed Prostate Cancer Trials

Many experts consider prostate cancer one of immunotherapy’s biggest disappointments. But a handful of patients don’t fit that narrative, and researchers are starting to uncover why.

Todays Updates

Schizophrenia: Nighttime Light Tied to Metabolic Dysfunction

Higher vs lower nighttime light exposure is associated with increased risk for obesity, hypertension, and dyslipidemia in patients with schizophrenia, a study suggests.

The Clues Hidden in Failed Prostate Cancer Trials

Many experts consider prostate cancer one of immunotherapy’s biggest disappointments. But a handful of patients don’t fit that narrative, and researchers are starting to uncover why.

Latest News

Concurrent palliative care use among young adults with advanced cancer is less than 20%, with substantial variation across cancer types.

In high-risk low-grade glioma, starting with temozolomide or radiotherapy yields similar survival.

Researchers aim to evaluate the effectiveness of ASCT as consolidation therapy for patients with advanced-stage natural killer/T-cell lymphoma who have attained their first complete remission.

A lung cancer trial was stopped early due to a high rate of fatal adverse events with the addition of thoracic radiotherapy to standard maintenance immunotherapy.

An FDA approval, striking CAR T data, and a field that can't agree on what to do next. Experts weigh in on the most contentious question in myeloma.

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

News All Time

PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC

Study adds to evidence that the widely used medications may interfere with immunotherapy efficacy via effects on the gut microbiome.

FDA Approves Subcutaneous Isatuximab for MM Indications

The drug can now be administered with the hands-free automated CirCLIQ on-body injector.

AI-Driven Biomarker Predicts Prostate Cancer Outcomes

The tool, based on histology only, may help identify patients most likely to benefit from triplet therapy.

Community Oncology Well Suited for Advanced Cancer Patients

Experts tout common characteristics of local physician practices that are beneficial to those with advanced disease.

Real-World EV Plus Pembro Success Seen in Urothelial Cancer

A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.

Germline Variants Predict Lobular Breast Cancer Recurrence

For women with invasive lobular carcinoma, pathogenic variants in breast cancer risk genes predict high odds of early recurrence.

MRI Enhancement Predicts Breast Cancer in BRCA Carriers

Higher background parenchymal enhancement on breast MRI may signal greater risk among women who carry BRCA mutations.

Polatuzumab Vedotin Boosts Survival in Relapsed DLBCL

Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly assigned to receive Pola-R-GemOx or R-GemOx.

Breast Cancer Incidence Rises in Asian American Women

A cross-sectional population-based study examines trends in invasive breast cancer incidence rates in Asian American, Native Hawaiian, and Pacific Islander ethnic groups.

Asian Women With Breast Cancer Outlive White Peers

Researchers seek to understand why Asian women fare better with the disease.

FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD

By carefully controlling the mix of stem and T cells, Orca‑T lowers the risk for graft-vs-host disease in adults with hematologic cancers.

Combined Models With AI Improve Breast Cancer Prediction

Combining mammography AI, polygenic, and clinical risk models improves 10-year breast cancer risk prediction compared with any single model.

Induction Immunotherapy Has Durable Survival Benefit in LACC

Patients with locally advanced cervical cancer who receive dual checkpoint blockade before standard chemoradiation have high 3-year survival, but outcomes are poorer for those with ‘cold’ tumors.

Time to Rethink Maintenance Pemetrexed in NSCLC?

For patients with advanced non-small cell lung cancer (NSCLC), adding pemetrexed to maintenance pembrolizumab may only increase toxicity, not survival.

Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?

Drug holidays are proving possible in hormone-sensitive metastatic prostate cancer — and some men stay off treatment for years.

CAR T Cells Produce 10-Year Remissions in Some With Lymphoma

Researchers evaluated long-term outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphomas receiving CAR T-cell therapy.

Recommended News For You

First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.

Transplantation Fails to Improve Survival in Mantle Cell Lymphoma

Diet and Prostate Cancer; TTFields OK'd for NSCLC; Cancer Studies Retracted

The biology of cancer as well as potential treatment options are examined by experts.

Number of cancer survivors in the US reaches 18.6 million—projected to exceed 22 million by 2035

Long-Term CAR-T Results in Lymphoma Confirm Early Promise

Spouses of Cancer Patients May Be at Increased Risk of Suicide

Recommended Articles For You

Targeted Therapy: Latest Advances, Learning Tools, Trials & Treatment Options Explained 

Rasburicase-Linked Methemoglobinemia in HCC: Risks, Mechanisms, and Management 

Beyond the Surface: Understanding the Silent Menace of Abdominal Hematomas 

Uncovering the Mysteries of Breast Cancer: The Journey to a Cure 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In a study, immune detection of oral cancers is linked to obesity.

2.

Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer

3.

Is Laughter Good for Blood Glucose Control?

4.

Novel analysis identifies markers that may predict failure of metastatic prostate cancer treatment

5.

GLP-1 RAs May Lower Hysterectomy Risk in Endometrial Cancer

1.

What You Need To Know About Secondary Polycythemia: Treatment & Symptoms

2.

Contemporary Approaches in Hematology for Specialists

3.

Understanding Lymphedema: Symptoms, Causes, and Treatment 

4.

Unlocking the Potential of Lutathera: A Revolutionary Cancer Treatment

5.

Understanding Iron Saturation Levels in Your Blood 

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V

2.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

3.

Updates on Standard V/S High Risk Myeloma Treatment- The Next Part

4.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot